Holen Sie sich die Stockscreener-App
13.61
2.09%
-0.29
Handel nachbörslich:
13.85
0.24
+1.76%
Schlusskurs vom Vortag:
$13.90
Offen:
$13.9
24-Stunden-Volumen:
206.86K
Relative Volume:
0.49
Marktkapitalisierung:
$193.34M
Einnahmen:
$13.11M
Nettoeinkommen (Verlust:
$-124.02M
KGV:
-0.9544
EPS:
-14.261
Netto-Cashflow:
$-107.25M
1W Leistung:
+13.13%
1M Leistung:
+1.19%
6M Leistung:
-43.81%
1J Leistung:
-12.98%
1-Tages-Spanne:
$13.60
$14.16
1-Wochen-Bereich:
$12.16
$14.90
52-Wochen-Spanne:
$11.60
$69.97
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Company Profile
Firmenname
Tonix Pharmaceuticals Holding Corp
Sektor
Branche
Telefon
212-980-9155
Adresse
200 CONNELL DRIVE, SUITE 3100, BERKELEY HEIGHTS, NY
Compare TNXP vs VRTX, REGN, ARGX, ALNY, INSM
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TNXP
Tonix Pharmaceuticals Holding Corp
|
13.61 | 197.46M | 13.11M | -124.02M | -107.25M | -14.26 |
VRTX
Vertex Pharmaceuticals Inc
|
434.30 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
763.04 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
748.25 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
330.34 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
163.81 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Tonix Pharmaceuticals Holding Corp Stock (TNXP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-04-18 | Eingeleitet | Noble Capital Markets | Outperform |
| 2019-04-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2017-08-18 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2016-09-07 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2016-02-17 | Bestätigt | Oppenheimer | Outperform |
| 2015-11-04 | Eingeleitet | Cantor Fitzgerald | Buy |
| 2015-06-12 | Eingeleitet | Oppenheimer | Outperform |
| 2015-02-17 | Bestätigt | ROTH Capital | Buy |
| 2014-09-29 | Bestätigt | ROTH Capital | Buy |
Alle ansehen
Tonix Pharmaceuticals Holding Corp Aktie (TNXP) Neueste Nachrichten
Tonix Pharmaceuticals stock hits new 52-week low: What's driving the action? - MSN
Tonix Pharmaceuticals Holding Corp at TD Cowen Healthcare Conference Transcript - GuruFocus
TNXP Stock Price, Quote & Chart | TONIX PHARMACEUTICALS HOLDIN (NASDAQ:TNXP) - ChartMill
Tonix Pharma CEO Lederman buys $63,099 in shares By Investing.com - Investing.com Canada
Tonix Pharma CEO Lederman buys $63,099 in shares - Investing.com
Tonix (NASDAQ: TNXP) CEO adds 5,000 shares via IRA purchase - stocktitan.net
Tonix Pharmaceuticals Holding Corp. (TNXP) stock price, news, quote and history - Yahoo Finance Australia
Tonix plans Phase 2 Lyme disease prevention study in 2027 By Investing.com - Investing.com Australia
Tonix Pharmaceuticals Holding Corp Presents Phase 1 Data And Outlines Planned Adaptive Phase 2 Field Study Of TNX-4800 For Prevention Of Lyme Disease - marketscreener.com
Tonix Pharma Advances TNX-4800 Lyme Disease Prevention Program - TipRanks
Tonix Pharmaceuticals (TNXP) Advances TNX-4800 Lyme Disease Trea - GuruFocus
Tonix plans Phase 2 Lyme disease prevention study in 2027 - Investing.com
Tonix Pharmaceuticals presents Phase 1 TNX-4800 data, aims for adaptive Phase 2 in H1 2027 - TradingView
Tonix (Nasdaq: TNXP) advances TNX-4800 Lyme prevention antibody on Phase 1 data - stocktitan.net
No U.S. Lyme preventive exists; Tonix tests 4-month single dose - stocktitan.net
Tonix Pharmaceuticals Announces Presentation of Phase 1 Data and Outlines Planned Adaptive Phase 2 Field Study of TNX-4800 for the Prevention of Lyme Disease, at the World Vaccine Congress Washington 2026 - Bitget
Recap Report: Can Tonix Pharmaceuticals Holding Corp stock outperform in a bear marketAnalyst Upgrade & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
Tonix Pharmaceuticals Stock Hits New 52-Week Low: What's Driving The Action? - Benzinga
Tonix Pharmaceuticals (NASDAQ: TNXP) puts reverse split and 2026 equity plan to vote - Stock Titan
TNXP Should I Buy - Intellectia AI
TNXP SEC FilingsTonix Pharmaceut 10-K, 10-Q, 8-K Forms - Stock Titan
Tonix Pharmaceuticals (NASDAQ:TNXP) Rating Lowered to "Sell" at Wall Street Zen - MarketBeat
Vanguard disaggregates holdings after realignment; reports 0 shares in Tonix (TNXP) - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — BOATS:TNXP - TradingView
Tonix doses first patient in migraine treatment study By Investing.com - za.investing.com
Tonix Pharmaceuticals Begins Phase 1 Study of Intranasal Oxytocin (TNX-1900) for Migraine and Craniofacial Pain Treatment - Minichart
Tonix Pharmaceuticals Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 (Intranasal Potentiated Oxytocin) to Assess Potential for Treating Migraine and Craniofacial Pain - Bitget
Tonix Pharmaceuticals (TNXP) Advances with Phase 1 Study on TNX-1900 - gurufocus.com
Tonix Pharma Begins Phase 1 Study of TNX-1900 - TipRanks
Tonix doses first patient in migraine treatment study - Investing.com
Tonix (NASDAQ: TNXP) doses first subject in TNX-1900 migraine study - Stock Titan
Tonix Pharmaceuticals Holding Corp Announces First Participant Dosed in Phase 1 Investigator-Initiated Pharmacodynamic Study of TNX-1900 - marketscreener.com
Q1 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
FY2028 Earnings Estimate for TNXP Issued By Zacks Research - Defense World
Why (TNXP) Price Action Is Critical for Tactical Trading - news.stocktradersdaily.com
FY2028 Earnings Forecast for TNXP Issued By Zacks Research - MarketBeat
Tonix Pharmaceuticals Holding Corp. (TNXP) Presents at BIO-Europe Spring 2026Slideshow - Seeking Alpha
TNXP: ~2500 Patients Have Initiated Treatment with Tonmya Following November 2025 Commercial Launch - research-tree.com
Tonix Pharmaceuticals Announces Presentations at World Vaccine Congress Washington 2026 - The Manila Times
Tonix Pharmaceuticals Announces Upcoming Presentations on TNX-4800 and TNX-801 at World Vaccine Congress 2026 - Quiver Quantitative
Lyme disease and mpox studies put Tonix on vaccine congress agenda - Stock Titan
Levels Update: What are Tonix Pharmaceuticals Holding Corps earnings expectationsEarnings Performance Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Tonix Pharmaceuticals (NASDAQ: TNXP) Seeks 1:2–1:250 Reverse Split; PwC Ratification - Stock Titan
Tonix Pharmaceuticals Holding Corp. Trade Ideas — LSX:A40VM0 - TradingView
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Tonix Pharmaceuticals says prescriptions for chronic pain drug top 4,200 since launch - MSN
Tonix Pharma CEO Makes Bold Insider Move Signaling Growing Confidence - TipRanks
Tonix Pharmaceuticals (NASDAQ:TNXP) CEO Seth Lederman Acquires 15,000 Shares - MarketBeat
Tonix Pharmaceuticals to Present at BIO-Europe Spring 2026 - Bitget
Finanzdaten der Tonix Pharmaceuticals Holding Corp-Aktie (TNXP)
Umsatz
Nettogewinn
Free Cashflow
ENV
Tonix Pharmaceuticals Holding Corp-Aktie (TNXP) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| LEDERMAN SETH | Chief Executive Officer |
Mar 18 '26 |
Buy |
14.89 |
15,000 |
223,350 |
15,001 |
| Taylor Carolyn E. | Director |
Aug 21 '25 |
Buy |
36.03 |
418 |
15,061 |
418 |
| Treco James | Director |
Aug 20 '25 |
Buy |
36.00 |
250 |
9,000 |
250 |
| LEDERMAN SETH | Chief Executive Officer |
May 15 '25 |
Buy |
21.55 |
4,000 |
86,200 |
4,005 |
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):